血中维生素D、血钙浓度及组织中钙敏感受体与乳腺癌的相关性研究

目的探讨25-羟基维生素D25-Hydroxy VitaminD，25（OH）D]、血钙（Serum calcium，Ca2＋）以及钙敏感受体（Calcium-sensing receptor，CaSR）与乳腺癌的关系。方法采用酶联免疫法和偶氮胂Ⅲ法检测乳腺癌及乳腺良性肿瘤患者血清25（OH）D和Ca2＋水平，采用免疫组织化学S-P法检测乳腺癌、乳腺良性肿瘤和瘤旁正常组织中CaSR的表达情况。结果乳腺癌组血清中25（OH）D水平明显低于乳腺良性病组（34．13±14．14）nmol／Lvs（50．29±25．65）nmol／L，t=2．870，P=0．001]，血清25（OH）D在淋巴结转移阳性乳腺癌患者中的水平明显低于淋巴结转移阴性患者（30．8±9．71）nmol／LVS（43．7±23．59）nmol／L，t=2．467，P=0．021]，乳腺癌组（88．9％）CaSR的阳性表达率明显高于良性乳腺组织（60．0％，χ2=6．717，P〈0．01）和瘤旁正常乳腺组织（60．0％，χ2=5．628，P〈0．05）。结论血清25（OH）D浓度和组织中CaSR的表达可能与乳腺癌的发生、发展及预后有关。

Study on serum levels of vitamin D and calcium and expression of tissue calcium-sensing receptor in the breast cancers

Objective To explore the relationship among 25-hydroxyvitamin D, serum calcium, calcium-sensing receptor, and breast cancer. Methods The expressions of calcium-sensing receptor （CaSR） in primary breast cancer, breast benign tumors, and normal breast tissue beside tumors were determined by immunohistochemistry S-P method as well as the concentration of serum 25 （OH） D and serum calcium in breast cancer and breast benign tumors by Enzyme-linked immunosorbent assay （ELISA）, Tribro- moarsenazo Ⅲ method. Results Serum 25 （OH） D level of breast cancer was significantly lower than the breast benign tumors （34. 13 ± 14. 14）nmol/L vs （50. 29 ±25.65） nmol/L, t =2. 870, P =0. 001 ]. Serum level of 25 （ OH ） D in lymph node metastasis positive patient was lower than that in negative group （30. 8 ± 9.71 ） nmol/L vs （43.7 ± 23.59 ） nmol/L, t = 2. 467, P = 0. 021 ]. The positive expression of CaSR in breast cancer（ 88.9% ）was higher than breast benign tumors （60%, χ2 = 6. 717, P 〈 0. 01 ） and normal breast tissue beside tumors（60% ,χ2 =5. 628, P 〈0. 05）. Conclusions Concentration of serum 25 （OH）D and expression of calcium-sensing receptor in the tissues may be associated with occurrence, development and prognosis of breast cancer.